364 filings
Page 5 of 19
6-K
5pd3k24fk1u
28 May 20
Current report (foreign)
11:56am
6-K
3gsja qgbvcrprqqo8
27 May 20
BioLineRx Announces Publication of Data from Ongoing
7:00am
6-K
bza wyaoud41b1px
26 May 20
BioLineRx Announces $9.0 Million Registered Direct Offering
8:45am
6-K
e94rfiknqdsjym0lbv
26 May 20
Current report (foreign)
8:10am
6-K
ox87qe8df
20 May 20
BioLineRx Reports First Quarter 2020 Financial Results
7:00am
6-K
x1jqgkuo8g48sctvtzua
12 Mar 20
BioLineRx Reports Year-End 2019 Financial Results
7:00am
6-K
6dxx4a0
5 Mar 20
Current report (foreign)
10:00am
6-K
4wj31
27 Feb 20
BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination with The COMBAT/KEYNOTE-202 Study
7:00am
6-K
zr8rmzsh
30 Jan 20
Extraordinary General Meeting of Shareholders
7:00am
6-K
w6h 7opkmwgf9d26er3
22 Jan 20
BioLineRx Completes Recruitment in Triple Combination
7:00am
6-K
cws4io28sljyxnl9
14 Jan 20
BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of
7:00am
6-K
u3pls1
13 Dec 19
BioLineRx Announces Updated Phase 2a Data from Triple
7:00am
6-K
0sbre491
5 Dec 19
BioLineRx Announces Preliminary Phase 2a Data from Triple
7:00am
6-K
mtl9otx7n1
12 Nov 19
Current report (foreign)
6:21am
6-K
fnkc58qqvizv
5 Nov 19
BioLineRx Announces BL-8040 in Combination with KEYTRUDA Shows Clinical Activity in Heavily Pretreated
9:00am
6-K
gpho8 2037
5 Nov 19
BioLineRx Presents Preclinical Data from Triple Combination
8:00am
6-K
vmkp816ok9m6ax1k
25 Sep 19
BioLineRx Announces Dosing of First Patient in Part 2 of
7:00am
6-K
detsgnn lhutpfd4
3 Sep 19
BioLineRx Successfully Completes Dose-Escalation Part of
7:00am
6-K
ky8e5h
6 Aug 19
BioLineRx Reports Second Quarter 2019 Financial Results
7:11am
6-K
nhd hil6ac
2 Jul 19
Current report (foreign)
10:00am